William Fairey - ChemoCentryx COO, Executive Vice President

CCXIDelisted Stock  USD 51.99  0.00  0.00%   

President

Mr. William Fairey is the Chief Operating Officer, Executive Vice President of ChemoCentryx Inc. Mr. Fairey brings to ChemoCentryx over 25 years of substantial pharmaceutical industry commercial experience. His most recent position was President of Actelion Pharmaceuticals U.S., where he led Actelion sales, marketing, medical, access and regulatory activities. Prior to that, Mr. Fairey served in numerous positions with Actelion Pharmaceuticals Ltd since 2001, including Head of Actelion Asia Pacific Region and President of Actelion Pharmaceuticals, Canada . Mr. Fairey started his pharmaceutical career with ParkeDavis U.S., where he held various positions on the commercial side of the business since 2018.
Age 52
Tenure 6 years
Professional MarksMBA
Phone650 210-2910
Webwww.chemocentryx.com
Fairey received his B.S., in Biology from the University of Oregon and his M.B.A. from Saint Mary College, California.

ChemoCentryx Management Efficiency

The company has return on total asset (ROA) of (18.55) % which means that it has lost $18.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (46.96) %, meaning that it created substantial loss on money invested by shareholders. ChemoCentryx's management efficiency ratios could be used to measure how well ChemoCentryx manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 73.2 M in liabilities with Debt to Equity (D/E) ratio of 0.31, which is about average as compared to similar companies. ChemoCentryx has a current ratio of 4.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ChemoCentryx until it has trouble settling it off, either with new capital or with free cash flow. So, ChemoCentryx's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ChemoCentryx sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ChemoCentryx to invest in growth at high rates of return. When we think about ChemoCentryx's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Amanda ParrilliDeluxe
45
Donald LeblancCimpress NV
49
Sean QuinnCimpress NV
45
Debra BradfordDeluxe
64
Keith BushDeluxe
49
Mark StewartTownsquare Media
55
Emily WhittakerCimpress NV
N/A
Julie LoosbrockDeluxe
57
Ashley HubkaCimpress NV
42
Katryn BlakeCimpress NV
43
Michael MathewsDeluxe
51
Scott SchatzTownsquare Media
45
Tracey EngelhardtDeluxe
59
Garry CapersDeluxe
47
Erik HellumTownsquare Media
59
Stuart RosensteinTownsquare Media
60
Lawrence GoldCimpress NV
47
Michael JosephsTownsquare Media
45
Jeffrey CotterDeluxe
57
Robert WorshekTownsquare Media
53
Dhruv PrasadTownsquare Media
39
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc. ChemoCentryx operates under Biotechnology classification in the United States and is traded on NMS Exchange. It employs 178 people. ChemoCentryx (CCXI) is traded on NASDAQ Exchange in USA and employs 178 people.

Management Performance

ChemoCentryx Leadership Team

Elected by the shareholders, the ChemoCentryx's board of directors comprises two types of representatives: ChemoCentryx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ChemoCentryx. The board's role is to monitor ChemoCentryx's management team and ensure that shareholders' interests are well served. ChemoCentryx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ChemoCentryx's outside directors are responsible for providing unbiased perspectives on the board's policies.
Israel Charo, Senior Vice President - Research
Jan Hillson, Senior Vice President - Drug Development
Geoffrey Parker, Independent Director
Susan Kanaya, CFO, Sr. VP of Fin. and Secretary
Petrus Bekker, Senior Vice President - Clinical and Medical Affairs
Joseph Feczko, Independent Director
Markus Cappel, Chief Bus. Officer and Treasurer
William Fairey, COO, Executive Vice President
Thomas Edwards, Independent Director
James Tyree, Independent Director
Henry McKinnell, Director
Rajinder Singh, Senior Vice President - Research
Roger Lucas, Lead Independent Director
Rita Jain, Independent Director
Thomas Schall, Founder, Chairman, CEO and Pres

ChemoCentryx Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ChemoCentryx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ChemoCentryx in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ChemoCentryx's short interest history, or implied volatility extrapolated from ChemoCentryx options trading.

Pair Trading with ChemoCentryx

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ChemoCentryx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ChemoCentryx will appreciate offsetting losses from the drop in the long position's value.

Moving together with ChemoCentryx Stock

  0.81NVO Novo Nordisk AS Financial Report 2nd of May 2024 PairCorr
  0.82NONOF Novo Nordisk ASPairCorr

Moving against ChemoCentryx Stock

  0.89WXIBF WuXi BiologicsPairCorr
  0.65ZTLLF ZonetailPairCorr
  0.57VRTX Vertex Pharmaceuticals Financial Report 6th of May 2024 PairCorr
The ability to find closely correlated positions to ChemoCentryx could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ChemoCentryx when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ChemoCentryx - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ChemoCentryx to buy it.
The correlation of ChemoCentryx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ChemoCentryx moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ChemoCentryx moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ChemoCentryx can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Consideration for investing in ChemoCentryx Stock

If you are still planning to invest in ChemoCentryx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ChemoCentryx's history and understand the potential risks before investing.
Stocks Directory
Find actively traded stocks across global markets
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators